|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:bupropion
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06AX12
|
|
gptkbp:brand
|
gptkb:Aplenzin
gptkb:Forfivo_XL
bupropion hydrochloride extended-release
|
|
gptkbp:contraindication
|
eating disorder
seizure disorder
abrupt discontinuation of alcohol
|
|
gptkbp:drugClass
|
antidepressant
aminoketone
|
|
gptkbp:eliminatedIn
|
urine
feces
|
|
gptkbp:features
|
black box warning for suicidal thoughts
|
|
gptkbp:form
|
extended-release tablet
300 mg tablet
150 mg tablet
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:halfLife
|
21 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Wellbutrin XL
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:levodopa
gptkb:phenytoin
gptkb:MAO_inhibitors
gptkb:ritonavir
gptkb:carbamazepine
cimetidine
antipsychotics
antiepileptics
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
GlaxoSmithKline
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
|
|
gptkbp:metabolism
|
liver (CYP2B6)
|
|
gptkbp:notRecommendedFor
|
children under 18
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
|
|
gptkbp:riskFactor
|
hypertension
seizures
neuropsychiatric symptoms
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
headache
insomnia
dry mouth
increased sweating
|
|
gptkbp:usedFor
|
gptkb:depression
gptkb:major_depressive_disorder
|
|
gptkbp:bfsParent
|
gptkb:Valeant_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|